BZI - Brainz Instruments

fair enough. I think its going places this company. has a good product and is in a field where there are only a few competitors that i know of. but Brainz product is much better. It has a 12month target price of 1.50 so im hoping we I can get that.

hear is the latest announcement.

BrainZ Business Update
US FDA Clearance sought for Seizure Detection Algorithm

BrainZ Instruments Limited (ASX:BZI) today announced it has lodged a submission with the United
States Food and Drug Administration (“FDA”) for its computer-assisted seizure detection
algorithm1. The BrainZ computer-assisted seizure detection algorithm will assist clinical staff to
detect seizure activity in “at risk” infants in the Neonatal Intensive Care Unit. It will be sold as an
upgrade to new and existing BrainZ BRM2 bedside brain monitor customers.
BrainZ CEO Dr Justin Vaughan says that “This additional sophistication to the BRM2 capability
further differentiates the BrainZ technology and adds a much-needed and highly valued additional
resource for those clinicians and support staff involved in managing at risk infants.”
BRM2 monitors are currently in use in 16 countries around the world, mainly within Neonatal
Intensive Care Units. In Australia, units retail for $25,000. BrainZ reported half-yearly sales growth
of 29% in its most recent investor update.
“Over the past quarter we have experienced strong sales growth and the seizure detection
capability feature will further increase the BRM2’s desirability catalysing further growth for BrainZ.
In terms of worldwide sales, the past three months has seen 31 BRM2 monitor sales compared to
25 in the previous six months and 5 in the same period last year. The sales delivered in the last
quarter include our first into South Africa, which is a market of considerable potential,” Dr Vaughan
added.
The BRM2 offers valuable insights into the neurological status of at risk infants and affords clinical
staff better information upon which to base patient management and treatment decisions. There is
limited but active competition to the BrainZ BRM2 in neonatal intensive care units but none of the
available competition is able to provide any form of automated seizure detection capability. The
addition of the computer-assisted seizure detection algorithm to the BRM2 would provide an
immediate additional point of difference over the current competition.
Dr Vaughan stated, “The addition of a seizure alarm system adds significant clinical utility to the
BRM2 monitor and considerably enhances the value proposition to our customers. It is a quantum
leap in terms of technology advancement. Also, the seizure detection method provides BrainZ with
a core technology platform to springboard into wider markets, including adult areas.”
1 510(k) Pre-Market Notification is being sought
The data supporting the seizure detection algorithm has been presented at multiple international
medical conferences over the past 18 months. The data presented indicated that the BrainZ
seizure detection algorithm had higher sensitivity, higher positive predictive value, higher
correlation, and a lower level of false positive detection than two other recognized seizure detection
algorithms. The latest presentation was made to the Pediatric Academic Societies’ meeting in San
Francisco in May 2006.
Dr Vaughan states that “The data behind the seizure detection system is extremely robust,
particularly its low rates of false positive detection which is critical for effective use within the
intensive care environment.
The fact that many of the world’s leading neonatal units are lining up to trial the algorithm is
testament to the attractiveness of the technology and the buzz associated with it throughout the
international community. The process from here is that we shall select leading centres for beta
testing of the seizure detection system and aim for full commercial release in the fourth quarter of
2006.”
Dr Vaughan advised that BrainZ had recently completed an extensive survey of all Australasian
neonatal customers. 100% of respondents indicated that the BRM2 monitor was benefiting the
management, treatment and care of their neonatal patients.
About BrainZ Instruments Limited: BrainZ is a New Zealand based medical device company
specialising in bedside brain monitoring technology. BrainZ listed on the ASX in December 2005.
BrainZ has filed for patent protection of the novel methodology behind the seizure detection system
in multiple international territories.
About FDA 510k: Section 510(k) of the US Food, Drug and Cosmetic Act requires device
manufacturers to notify FDA, at least 90 days in advance, of their intent to market a medical
device. This is known as Premarket Notification - also called PMN or 510(k). It allows FDA to
determine whether the device is equivalent in terms of safety and effectiveness to a legally
marketed device.

this is also very interesting if you would like to hear about the company.


AUDIO BROADCAST – BZI – Introduction to BrainZ Instruments

BrainZ (ASX:BZI) wish to inform the market of an audio broadcast with Dr Justin Vaughan,
Chief Executive Officer who will be giving a general introduction to BrainZ Instruments.
The presentation is available at www.boardroomradio.com at 11am (AEST) on Thursday June
8, 2006 - the presentation will also be archived at www.boardroomradio.com for future ondemand
listening.

Here is a very promising report from the company.

BrainZ quarterly sales growth up 120%

BrainZ Instruments Limited (ASX: BZI) today announced strong quarterly sales
growth for the period ending May 2006. “During the past 3 months, total product sales amounted to NZ$668,000” commented Dr Justin Vaughan, Chief Executive Officer of BrainZ.

“This is an increase in sales of over 120% compared to the previous quarter and over 450% greater than the same quarter last year. This sales growth, which is in part due to an increase in our distributors demo stock levels, is very encouraging and a good sign of the increasing global adoption of the BrainZ technology.”

I have hopped into this one in the last few days.

Since listing in December, Brainz has not put a foot wrong and looks to have significantly derisked with sales having picked up exactly in line (actually. . . slightly in front of) JT Campbell expectations from the time of the float.

This one could easily move 40% on only a little bit of news. With a capitalisation of $30 million, and $10 million cash at bank. . . . it certainly is not overpriced if it delivers on its potential.

The question for anyone thinking about buying right now is whether there is much stock available at current prices. I have taken out everything sub-51 cents in the last few days. . . . the question is whether there is more stock available off screen. This should become clear in the near term.

I suspect that there is a bit of stock avaialable in the 50s. . . . but could dry up very quickly on news. Next date for news will be cashflow statement at end september. This should look great compared to the last one as we know that cash from sales in the quarter to May was deferred to the August quarter. Suspect that August will still show a cash outflow. . . . but that this will change by early 07.

your right. it is a great stock however it has a small turnover of stock each day. most days there are 1 or no trades. it has a recommend price high for $1.50 but only a few people who were able to get the report saw the research reports. the funny thing is those who were able to see it were mostly all the investors already in the company. you had to prove that you were a sophisticated investor to get your hands on a copy. currently the stock is way underpriced in my opinion and I think that over the next year it will pick up big time. especially as it is a possible takeover target by GE in the near future.

Twojacks. . . i never like to rely on small tech-style companies being taken over by their big relationship partners. you can grow old waiting for it to happen. Just look at ADA - for at least eight years people have been saying "buy now - it might get taken over by Lockheed Martin tomorrow".

to GE, BZI is just another product supplier.

therefore, while a takeover by GE is ALWAYS possible, BZI will either make money for us on its merits. . . or not.

also. . . .don't get too sucked in by price targets. while i have huge respect for pethica, it is easy to find a broker who will put a big price target on almost any biotech that is rolling out a new product. the maths is so easy. . . . if it achieves market share of x%, the company is worth $y per share.

BZI is still to achieve successful rollout. all that we know at this point is that the company has achieved sales of 10 units per month in recent months. This is in keeping with expectations at the time of the float.

IF the company makes the next "step up" in growth to, say, 20 units per month in FY07 we can say that the company is one step closer to creating real value. HOWEVER, it will only be when the company is reliably selling, say, 50 units per month that you can be confident that the company is worth a whole lot more than today's trading price.

if you are looking for Pethica's original 17 page report on the company it is available. . . .someone posted it on the BZI thread in another chat site. I found it compelling. . .. but you have to realise (as does Pethica) that BZI remains SPECULATIVE.

totally agree with what your saying. I was just stating what he has said. can you send me a link of that other forum to BZI. in reference to the GE takeover I am not waiting for it to hppen. it was apparently said that this would open new doors for GE compared to other products which they supply.

Biggest gainer on the ASX today. Up 77.3 %, and all it took was AUD1950.00 :. How's that for an outstanding breakout